Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021490 | 0.85 | CA2 (0.39) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL20698977 | 0.85 | CA2 (0.39) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL21899248 | 0.82 | FFAR2 (0.38) | LOXL2LOX | |
| SCHEMBL7554129 | 0.81 | CA2 (0.35) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL21963159 | 0.81 | CA2 (0.34) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL22013606 | 0.74 | — | — | |
| SCHEMBL5515612 | 0.74 | CA2 (0.44) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL9095726 | 0.73 | CA2 (0.35) | CA2CA1CA9CA12LOXL2 | |
| SCHEMBL9095254 | 0.72 | CA2 (0.36) | CA2 | |
| SCHEMBL1241096 | 0.71 | ADORA3 (0.56) | CA2CA1CA9CA12LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102574-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| CN-1298709-C | Thiophene-amd thiazolesulfonamides as antineoplastic agents | LILLY CO ELI (US) | 2007-02-07 | — | — | CN | disclosed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | disclosed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| CN-1575286-A | Thiophene-amd thiazolesulfonamides as antineoplastic agents | LILLY CO ELI (US) | 2005-02-02 | — | — | CN | disclosed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | TPMT, TST, MGMT | CA2 1394/4885CA1 1002/4885CA9 356/4885 |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ALDH1A2, MGMT, NR2E3 | CA2 2965/4885CA1 4169/4885CA9 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.